Park Medi World Shares Fall 10%: Q2 Profit Drops 31%, Margins Slide

Park Medi World’s Expansion Push Faces a Margin Test

Record revenue could not offset weaker profitability as newly added hospital capacity weighed on near-term performance.

Revenue growth did not translate into stronger earnings

Park Medi World’s consolidated net profit after tax fell to ₹54.5 crore in Q2 FY27 from ₹78.7 crore a year earlier, a 31% decline. Profit was down 38% from the preceding quarter, a steeper sequential fall that underlines the pressure on earnings in the latest period.

Revenue from operations, by contrast, increased 24.6% year on year to ₹511 crore, the company’s highest-ever quarterly figure. It was also up 7% from ₹475.7 crore in the quarter ended June. The divergence between sales growth and profit performance is the key feature of the results: higher revenue has not, so far, protected earnings from rising costs and the near-term demands of expansion.

Cost pressure squeezed operating margins

EBITDA declined 9.7% year on year to ₹101.7 crore from ₹112.6 crore. The company attributed the weaker operating performance to higher costs for materials and employees. EBITDA margin fell to 19.9% from 27.5% a year earlier, a contraction of 758 basis points.

For investors, the margin decline matters because it shows that the quarter’s revenue gains came alongside a weaker conversion of sales into operating earnings. The company’s explanation also points to a transition cost: newly commissioned capacity can take time to build activity, while associated staffing and operating expenses may affect profitability before the facilities ramp up. The results do not establish how quickly that recovery will occur.

A large bed pipeline raises the execution stakes

Management said Park Medi World added 680 beds in six months through its Rudrapur and Panchkula facilities, taking total capacity to 4,290 beds. It said the new facilities’ onboarding had affected occupancy and profitability, as they require time to ramp up.

The company expects to add 1,430 beds in FY27 through the commissioning of Febris in Delhi, the Palam Vihar expansion in Gurugram, Mehar Hospital in Zirakpur and its Kanpur facility. Management described this as about 40% above FY26 closing capacity and the largest addition in the company’s history. That ambition creates a clear operating test: additions must translate into patient activity and revenue without keeping costs elevated for too long. The supplied results do not quantify the expected contribution or ramp-up timeline for each facility.

The share-price response reflects the earnings miss

After the results were released during market hours, the shares touched ₹231 on the BSE, down 9.9% and close to the ₹230.80 lower price band. At 11.55 am, they were down 5.6% at ₹242, while the Sensex declined 0.45% to 81,544. The sharp intraday reaction suggests investors focused on falling profit and margins despite record revenue.

The stock had listed at ₹155.60, against an IPO price of ₹162, and remained 58% above the IPO price and 65% above its listing price, based on the figures provided. Those gains offer context, but do not resolve the question raised by the quarter: whether planned capacity growth can be absorbed while restoring operating profitability.

Key Highlights

• Q2 FY27 net profit fell 31% year on year to ₹54.5 crore.
• Revenue rose 24.6% to a record ₹511 crore.
• EBITDA dropped 9.7% to ₹101.7 crore as costs increased.
• EBITDA margin contracted 758 basis points to 19.9%.
• Management expects 1,430 beds to be added in FY27.

Investor Note: Park Medi World’s expansion plans offer a potential path to future growth, but the latest quarter shows that capacity additions can pressure earnings before they mature. Investors may want to track whether revenue growth is accompanied by a recovery in margins and profit as new facilities ramp up.